Partners

Institut català d'oncología

Bioempren

Institut d'investigació Biomèdica de Bellvitge

Acció

Centro para el desarrollo tecnologico industrial

Sant Joan de Déu



VCN BIOSCIENCES SL is the leader of different collaborative projects:

VIRAHN project: Combining VCN-01 with an immunocheckpoint inhibitor (anti-PD-L1 antibody) for the treatment of patients with recurrent/metastatic squamous cell carcinoma of the Head and Neck Phase 1 who has experienced previous resistance to PD1/PD-L1 checkpoint inhibitors. This project is based in a Phase 1 clinical trial, in collaboration with INSTITUT CATALÀ D'ONCOLOGIA and has Astra Zeneca as partner of choice.

Project Cure4RB project: Development of VCN-01 for pediatric retinoblastoma and Phase 1 clinical trial (RTC-2015-4319-1), in which the following partners have been implied: FUNDACIÓ HOSPITAL SANT JOAN DE DÉU, REIG JOFRÉ GROUP, & INSTITUT CATALÀ D'ONCOLOGIA. This project has received funding from Spanish MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD and the European Union (FEDER) by means of RETOS program in its 2015 call.

Project ADELVAC project: ADENOVIRUS with epitope deletions for vaccinacion (IPT-2012-0551-010000), in which the following partners have been implied: REIG JOFRÉ GROUP, INSTITUT CATALÀ D'ONCOLOGIA & INSTITUTO DE SALUD CARLOS III. This project has received funding from Spanish MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD and the European Union (FEDER) by means of INNPACTO program in its 2012 call la Frase.

ministerio de economia y competitividad

Fondo europeo de desarrollo regional